Public-Private Genome Debate Resurfaces

Smoldering differences between the Celera Genomics Group and the Human Genome Project erupted last month as three leaders of the international public consortium published an online article in the Proceedings of the National Academy of Sciences (PNAS)1 criticizing the results published last year by Celera.2 For the first time in scientific literature, Robert Waterston of Washington University, Eric Lander of the Whitehead Institute for Biomedical Research's Center for Genome Research, and John Su

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Celera scientists published a commentary two weeks later saying that the simulations performed by Waterston and colleagues were flawed and based on false assumptions.4

Philip Green, Howard Hughes Medical Institute investigator and professor of genome sciences at the University of Washington, argues that Adams is backpedaling. "The explicit claim is in Celera's [2001] paper that they did an assembly by the whole genome approach. You can't allow false claims to persist in the literature." Green also published a commentary dispelling, among other things, the widely held notion that the competition Celera brought to the human genome project was a good thing, saying instead that it "has the downside of encouraging shortcuts that may compromise the ultimate result."5

While some sequencing-center heads maintain these criticisms, others have ducked the fray. Richard Gibbs, director of the Baylor College of Medicine genome-sequencing center has had the help of Celera in the effort to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Brendan Maher

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo